中国呼吸与危重监护杂志

中国呼吸与危重监护杂志

甲状腺转录因子-1 对不同化疗方案治疗晚期肺腺癌患者的预后价值研究

查看全文

目的探讨甲状腺转录因子-1(TTF-1)对不同化疗方案治疗晚期肺腺癌患者的预后价值。方法将 2013 年 12 月至 2015 年 12 月收治的 126 例晚期肺癌患者按照化疗方案的不同分为三组:培美曲塞+奈达铂组(PEM+NDP 组)、培美曲塞+顺铂/卡铂组(PEM+DDP/CBP 组)以及三代化疗药+顺铂/卡铂组(3G agent+DDP/CBP 组)。采用电话、门诊等方式进行随访,随访截止时间为 2017 年 4 月。分析 TTF-1 对上述三种治疗方案疗效的预测价值。结果三种不同化疗方案在疾病控制率、客观缓解率方面差异无统计学意义(均 P>0.05)。培美曲塞+奈达铂组 3 年生存率显著高于培美曲塞+顺铂/卡铂组以及三代化疗药+顺铂/卡铂组(9.68% 比 5.56%、6.80%,均P<0.05)。体力状况 ECOG 评分、脑转移是各化疗方案治疗预后的独立危险因素,TTF-1 是培美曲塞+奈达铂治疗疗效的独立危险因素。结论TTF-1 是培美曲塞+奈达铂化疗后预后的独立危险因素,而对三代化疗药+顺铂/卡铂以及培美曲塞+顺铂/卡铂治疗预测作用不明显。

ObjectiveTo investigate the predictive value of thyroid transcription factor-1 (TTF-1) in the treatment of advanced lung adenocarcinoma with different chemotherapy regimens.MethodsA total of 126 patients with advanced lung cancer were divided into three groups according to the chemotherapy regimen, namely a pemetrexed+nedaplatin group (PEM+NDP group), a pemetrexed+cisplatin/carboplatin group (PEM+DDP/CBP group) and a third-generation (3G) chemotherapy+cisplatin/carboplatin group (3G agent+DDP/CBP group). The predictive value of TTF-1 in the above three treatment regimens was analyzed. The patients were followed up by telephone or outpatient visit until April 2017.ResultsThere were no significant differences in disease control rate or objective response rate between the three different chemotherapy regimens (all P>0.05). The survival rate of PEM+NDP group was significantly higher than that of PEM+DDP/CBP group and 3G agent+DDP/CBP group (9.68%vs. 5.56% and 6.80%, both P<0.05). ECOG score and brain metastasis were independent risk factors for the prognosis of chemotherapy regimens. TTF-1 was an independent risk factor for PEM+NDP therapy.ConclusionTTF-1 is an independent risk factor for PEM+NDP chemotherapy, but not for 3G agent + DDP/CBP or PEM+DDP/CBP regimens.

关键词: 晚期肺腺癌; 甲状腺转录因子 -1; 化疗; 生存分析

Key words: Advanced lung adenocarcinoma; Thyroid transcription factor-1; Chemotherapy; Survival analysis

引用本文: 门翔, 党强, 段秋立, 郑大炜, 尚喜雨. 甲状腺转录因子-1 对不同化疗方案治疗晚期肺腺癌患者的预后价值研究. 中国呼吸与危重监护杂志, 2018, 17(1): 59-65. doi: 10.7507/1671-6205.201706023 复制

登录后 ,请手动点击刷新查看全文内容。 没有账号,
登录后 ,请手动点击刷新查看图表内容。 没有账号,
1. Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thorac Oncol, 2014, 9(2): 154-162.
2. Qian HH, Xu TS, Cai XQ, et al. Prognostic value of TTF-1 expression in patients with non-small cell lung cancer: a meta-analysis. Clin Chim Acta, 2015, 451(Pt B): 208-214.
3. Fiala O, Pesek M, Skrickova J, et al. Thyroid transcriptionfactor 1 expression is associated with outcome of patients with non-squamous non-small cell lung cancer treated with pemetrexed-based chemotherapy. Tumour Biol, 2017, 39(2): 1010428317691186.
4. Chung KP, Huang YT, Chang YL, et al. Clinical significance of thyroid transcription factor-1 in advanced lung adenocarcinoma under epidermal growth factor receptor tyrosine kinase inhibitor treatment. Chest, 2012, 141(2): 420-428.
5. Ettinger DS, Wood DE, Akerley W, et al. NCCN Guidelines Insights: Non-Small Cell Lung Cancer. Version 4. 2016. J Natl Compr Canc Netw, 2016, 14(3): 255-264.
6. 肖小意, 戴广海, 孙琼, 等. 甲状腺转录因子-1 在晚期非小细胞肺癌中的表达及意义. 军医进修学院学报, 2012, 33(12): 1293-1295.
7. Lin L, Zhao J, Hu J, et al. Comparison of the efficacy and tolerability of gefitinib with pemetrexed maintenance after first-line platinum-based doublet chemotherapy in advanced lung adenocarcinoma: single-center experience. Onco Targets Ther, 2016, 9: 6305-6314.
8. 刘联, 王秀问, 黎莉, 等. 含顺铂的三组联合化疗方案治疗晚期非小细胞肺癌的随机对照临床研究. 癌症, 2006, 25(8): 990-994.
9. 黄芳, 姜达, 李颖, 等. 晚期肺腺癌化疗方案的优化. 肿瘤防治研究, 2015, 42(7): 687-692.
10. 姜正华, 黄谦, 葛辉, 等. 不同化疗方案对晚期非小细胞肺癌患者肺功能的影响. 临床肿瘤学杂志, 2012, 17(12): 1089-1092.
11. 孔斌. 不同含铂治疗方案在晚期非小细胞肺癌患者中的应用效果. 中国医药导报, 2016, 13(35): 102-105.
12. Pesce GA, Klingbiel D, Ribi K, et al. Outcome, quality of life and cognitive function of patients with brain metastases from non-small-cell lung cancer treated with whole brain radiotherapy combined with gefitinib or temozolomide. A randomised phase II trial of the Swiss Group for Clinical Cancer Research (SAKK 70/03). Eur J Cancer, 2012, 48(3): 377-384.
13. Shen N, Fu P, Cui B, et al. Associations between body mass index and the risk of mortality from lung cancer: a dose-response PRISMA-compliant meta-analysis of prospective cohort studies. Medicine (Baltimore), 2017, 96(34): e7721.
14. 牛媛媛, 王慧娟, 张国伟, 等. 晚期肺腺癌患者血清中甲状腺转录因子-1 表达与表皮生长因子受体突变的关系. 中华结核和呼吸杂志, 2014, 37(12): 919-924.
15. Konno H, Saito H, Nanjo H, et al. Rapid immunohistochemistry with thyroid transcription factor-1 for pulmonary adenocarcinoma. Ann Thorac Surg, 2017, 104(2): 471-476.
16. Griesing S, Kajino T, Tai MC, et al. Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells. Cancer Sci, 2017, 108(7): 1394-1404.
17. Piljić Burazer M, Mladinov S, Ćapkun V, et al. The utility of thyroid transcription factor 1 (TTF-1), napsin A, excision repair cross-complementing 1 (ERCC1), anaplastic lymphoma kinase (ALK) and the epidermal growth factor receptor (EGFR) expression in small biopsy in prognosis of patients with lung adenocarcinoma -- A retrograde single-center study from Croatia. Med Sci Monit, 2017, 23: 489-497.
18. Tran L, Mattsson JS, Nodin B, et al. Various antibody clones of napsin A, thyroid transcription factor 1, and p40 and comparisons with cytokeratin 5 and p63 in histopathologic diagnostics of non-small cell lung carcinoma. Appl Immunohistochem Mol Morphol, 2016, 24(9): 648-659.
19. Käsmann L, Janssen S, Rades D. Prognostic factors including the expression of thyroid transcription factor 1 (TTF1) in patients irradiated for limited-disease small cell lung cancer. Anticancer Res, 2016, 36(7): 3499-3503.
20. Nakahara Y, Hosomi Y, Saito M, et al. Predictive significance of thyroid transcription factor-1 expression in patients with non-squamous non-small cell lung cancer with wild-type epidermal growth factor receptor treated with erlotinib. Mol Clin Oncol, 2016, 5(1): 14-18.